Stock Analysis of Avalo Therapeutics Inc (AVTX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code AVTX
Close 9.59
Change -0.050 / 0.519 %
Volume 64410.00
Vol Change 39710.00 / 160.77 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Avalo Therapeutics Inc
PE (TTM)

-0.0321

Very Poor
Price / Book

-0.249

Very Poor
Price / Sales

3.17

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

9917.31 K

Enterprise Value

3039.31 K

ROA (TTM)

-304.70

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-9853.72

Very Poor
Revenue

87.54 %

2249.00 K
Net Profit

20.33 %

-33188.00 K
Debt to Equity

0.074

Excellent
Altman Z Score

-26.11

Very Poor
Quick Ratio

0

Poor
Cash Ratio

1.61

Indecisive


Highs/Lows of Avalo Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week10.85 11.61 % 1.54 % 11.28.917413-May-2417-May-24
Two Week14.36 33.22 % 3.42 % 14.998.917406-May-2417-May-24
One Month13.62 29.59 % 5.60 % 17.498.917429-Apr-2417-May-24
Three Month4.46 115.02 % 5.95 % 34.464.1828-Mar-2420-Feb-24
Six Months21.6 55.60 % 17.48 % 34.463.950128-Mar-2417-Jan-24
One year669.6 98.57 % 27.52 % 1130.43.950123-Jun-2317-Jan-24
Two year878.976 98.91 % 29.70 % 1680.03.950107-Nov-2217-Jan-24
Five year15465.6 99.94 % 85.46 % 1296.00.033318-Jan-2312-Dec-23


Technical View of Avalo Therapeutics Inc
RSI

35.89

Bearish
MACD

-0.730

Bearish
ADX

24.07

Neutral
Super Trend

13.95

Mild Bearish
Williams %R

-92.09

Mild Bullish
CCI

-119.95

Mild Bullish


EMA 5

10.23

Strong Bearish
EMA 15

11.80

Strong Bearish
EMA 50

11.72

Strong Bearish
EMA 100

20.70

Strong Bearish
SMA 100

8.61

Strong Bearish
SMA 200

17.49

Mild Bearish
SMA 5 / 20

10.21 / 13.10

Strong Bearish
SMA 15 / 50

12.77 / 11.55

Bullish
SMA 50 / 200

11.55 / 17.49

Mild Bearish




Charts of Avalo Therapeutics Inc


Returns of Avalo Therapeutics Inc with Peers
Period / StockAVTXGENEASLNBTCY
1 Week-11.61%-0.437%7.96%-13.47%
1 Mth-29.59%-27.85%-9.63%-16.54%
3 Mth115.02%14.00%-14.67%9.28%
6mth-55.60%-37.96%-56.92%7.07%
1 Year-98.57%-51.59%-89.98%-72.39%
2 Year-98.91%-64.09%-80.50%-83.33%
5 Years-99.94%-89.73%-97.54%-76.13%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Avalo Therapeutics Inc with Peers
Ratio / StockAVTXGENEASLNBTCY
PE-0.0321-95.05-1.41-0.641
P/B-0.249205.80-24.32-0.427
ROA-304.70-144.43-92.21-233.66
ROE0-216.5200
Debt To Equity0.0740.0272-2.02-0.258
Revenue2249.00 K
87.54 % 		8686.12 K
27.83 % 		12000.00 K
0 % 		9639.06 M
125896 %
Net Income-33188.00 K
20.33 % 		-11750.92 K
64.79 % 		-45188.26 K
12.06 % 		-19533.68 M
66955.83 %


Technicals of Avalo Therapeutics Inc with Peers
Technical / StockAVTXGENEASLNBTCY-
ADX24.0717.5815.4217.28
CMF-0.127-0.0197-0.593-0.332
MFI20.3240.5429.2144.78
RSI35.8942.5546.8538.39
MACD Abv SignalFalseTrueTrueFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Avalo Therapeutics Inc

Address : 540 Gaither Road, Rockville, MD, United States, 20850
Tel : 410 522 8707
URL : https://www.avalotx.com
Code : AVTX, ISIN : US05338F2074, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 13_Nov_2015
Employee Count : 19

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.


Note : All Data Generated at the End of Trading Hours (EOD Data)